Clinical trials: Relapsing-remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of Part A is to determine the safety and tolerability of natalizumab administered over 24 weeks in Japanese participants with relapsing-remitting multiple sclerosis (MS).
- Trial name
- Tysabri Japan (NCT01440101)
- Testing
- Natalizumab (BG00002)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
Study to evaluate the effectiveness of ofatumumab in Italian RRMS patients in the real-life setting.
- Trial name
- NCT06345157
- Testing
- Ofatumumab
- Where
- 31 sites in Italy
- Volunteers
- 379 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
The purpose of this study is to evaluate the efficacy and safety of peginterferon beta-1a produced by CinnaGen compared with CinnoVex® (CinnaGen) in subjects with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT05242133
- Testing
- Pegylated interferon beta-1a, Interferon Beta-1A Prefilled Syringe
- Where
- Iran
- Volunteers
- 168 people
- Sponsor
- Cinnagen
Relapsing-remitting Multiple Sclerosis (RRMS)
MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
- Trial name
- ASSESS (NCT01633112)
- Testing
- fingolimod, glatiramer acetate
- Where
- 130 sites in United States, Argentina and 5 more
- Volunteers
- 1,064 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Fingolimod Versus Interferon Beta 1b in Cognitive Symptoms
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression…
- Trial name
- Cognition (NCT01333501)
- Testing
- Fingolimod, Interferon beta 1b
- Where
- 26 sites in Germany, Italy
- Volunteers
- 151 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
The primary objective is to evaluate the safety and tolerability of natalizumab (BG00002, Tysabri®) in the study population (Russian participants with relapsing remitting multiple sclerosis).
- Trial name
- NCT02142205
- Testing
- BG00002
- Where
- 11 sites in Russia
- Volunteers
- 100 people
- Sponsor
- Biogen